2 results
Approved WMOCompleted
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.
Approved WMOCompleted
Primary objectives: Dose-expansion:To evaluate the antitumor activity of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in immunotherapy-naïve subjects with advanced or metastatic ccRCC as based on investigator assessed…